Efficacy and Safety of Acupuncture Combined with Hydroxychloroquine in Treating Primary Sjögren's Syndrome: A Randomized Controlled Trial.

Authors

Jian-Bin Li, Hang Lu, Yi-Hua Fan, Wei Liu

Published in

Chinese journal of integrative medicine. Oct 02, 2026. Epub Oct 02, 2026.

Abstract

To evaluate the efficacy and safety of acupuncture combined with hydroxychloroquine (HCQ) in patients with primary Sjögren's syndrome (pSS) and to explore the underlying mechanisms of acupuncture effect.
This study was designed as a randomized controlled trial (RCT) and included 138 pSS patients who were equally and randomly assigned to the treatment group or the sham acupuncture control group (69 cases in each group). The control group received HCQ sulfate tablets (0.2 g, twice daily) combined with sham acupuncture, whereas the treatment group received real acupuncture in addition to HCQ treatment. Acupuncture at Baihui (GV 20), Zusanli (ST 36), Sanyinjiao (SP 6), Taixi (KI 3), etc. was administered. Both groups underwent 8 treatment courses, with a 4-week follow-up. The primary efficacy endpoint was the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score. The secondary endpoints included clinical symptom scores, laboratory indicators, and scores for anxiety (Hospital Anxiety and Depression Scale-anxiety, HADS-A) and depression (HADS-D). Safety assessments including vital signs monitoring and laboratory tests were conducted at weeks 0, 2, 4, 6, and 8, and adverse events were evaluated throughout the study.
A total of 57 patients in the treatment group and 62 in the control group completed the full course of treatment. After treatment, both groups presented a reduction in ESSPRI scores, eye dryness numerical rating scale (NRS), mouth dryness NRS, and EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scores compared with the baseline values and an increase in the salivary flow rate, Schirmer test results, and tear film break-up time (BUT) scores compared with the baseline values (P<0.05). The erythrocyte sedimentation rate (ESR), IgG, and IgA level were significantly lower than those at baseline (all P<0.05). Compared with the control group, the treatment group had significantly lower ESSPRI scores, eye dryness NRS, and mouth dryness NRS and significantly higher salivary flow rates, Schirmer test results, and BUT scores (all P<0.05), as well as lower HADS-A scores (P<0.001); both groups had a statistically significant difference in FAS analysis of HADS-D scores (P=0.020), and the difference was more significant in PPS analysis (P=0.003), with significant improvement within the treatment group (P=0.012). The incidence of adverse events was not significantly different between the two groups (P>0.05).
Acupuncture combined with HCQ treatment is more effective than HCQ alone in improving dry mouth and dry eye symptoms in pSS patients, with a good safety profile. Additionally, acupuncture treatment may indirectly alleviate anxiety and depression symptoms by improving clinical outcomes such as dry mouth and dry eye. (Registration No. TCTR20230116003).

PMID:
42826003
Bibliographic data and abstract were imported from PubMed on 03 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.